Including more than 450 people with Type 1, 2, or 3 spinal muscular atrophy (SMA)

Evrysdi received FDA approval based on results from the first 12 months of 2 main ongoing studies

FIREFISH: infants with Type 1 SMA

SUNFISH: Children and adults with Type 2 or 3 SMA

A third, supportive study is currently looking at the safety of Evrysdi in people previously treated for SMA

JEWELFISH: Safety in people previously treated for SMA

*Motor function was measured using several tools including the Bayley Scales of Infant and Toddler Development Gross Motor Scale-Third Edition (BSID-III), the Motor Function Measure-32 Items (MFM-32), and the Revised Upper Limb Module test (RULM).

MySMA Support

Learn more about Evrysdi, financial support options, prescription shipment, and more